Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail)

v3.8.0.1
Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Noncontrolling Interest [Line Items]          
NCI equity share     $ 101,676   $ 60,668
Net loss attributed to non-controlling interests $ (9,191) $ (3,975) (17,355) $ (12,324) (16,195)
Non-controlling interests in consolidated entities 84,321   84,321   44,473
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     17,306   (494)
Net loss attributed to non-controlling interests (1,015) [1] (47) (1,329) (231) (349)
Non-controlling interests in consolidated entities 15,977   15,977   (843)
Coronado SO Co, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (236)   (217)
Net loss attributed to non-controlling interests (15) (4) (22) (14) (19)
Non-controlling interests in consolidated entities (258)   (258)   (236)
Mustang Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     47,840   12,376
Net loss attributed to non-controlling interests (3,241) [1] (204) (8,268) (363) (1,805)
Non-controlling interests in consolidated entities 39,572   39,572   10,571
Checkpoint Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     22,368   32,160
Net loss attributed to non-controlling interests (3,437) [2] (3,254) (10,144) [2] (10,767) (11,733)
Non-controlling interests in consolidated entities 12,224   12,224   20,427
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (535)   (192)
Net loss attributed to non-controlling interests (103) (104) (150) (333) (355)
Non-controlling interests in consolidated entities (685)   (685)   (547)
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (1,848)   (612)
Net loss attributed to non-controlling interests (376) $ (362) (975) $ (616) (1,155)
Non-controlling interests in consolidated entities (2,823)   (2,823)   (1,767)
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (239)   4
Net loss attributed to non-controlling interests 24   (60)   (158)
Non-controlling interests in consolidated entities (299)   (299)   (154)
Caelum [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     7    
Net loss attributed to non-controlling interests (835)   (1,086)    
Non-controlling interests in consolidated entities (1,079)   (1,079)    
National Holdings [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     17,022   17,643
Net loss attributed to non-controlling interests (27)   4,845   (621)
Non-controlling interests in consolidated entities 21,867   21,867   $ 17,022
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (9)    
Net loss attributed to non-controlling interests (166)   (166)    
Non-controlling interests in consolidated entities $ (175)   $ (175)    
[1] Mustang and Avenue are consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s and Avenue’s Class A preferred shares which provide super-majority voting rights.
[2] Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights